Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer DOI Creative Commons
Manoj Amrutkar,

Sander Johannes Thorbjørnsen Guttorm,

Anette Vefferstad Finstadsveen

et al.

Molecular Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 15, 2024

Neoadjuvant chemotherapy (NAT) is increasingly used for the treatment of non-metastatic pancreatic ductal adenocarcinoma (PDAC) and established as a standard care borderline resectable locally advanced PDAC. However, full exploitation its clinical benefits limited by lack biomarkers that assess response. To address this unmet need, global metabolomic profiling was performed on tumor tissue paired serum samples from patients with treatment-naïve (TN; n = 18) neoadjuvant leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride oxaliplatin (FOLFIRINOX)-treated (NAT; 17) PDAC using liquid chromatography mass spectrometry. Differentially abundant metabolites (DAMs) in TN versus NAT groups were identified their correlation various parameters assessed. Metabolomics 40 five DAMs In general, associated amino acid nucleotide metabolism lower compared to TN. Four DAMs-3-hydroxybutyric (BHB), 3-carboxy-4-methyl-5-propyl-2-furanpropanoic (CMPF), glycochenodeoxycholate citrulline-were common both showed similar pattern differential abundance groups. A strong positive observed between carbohydrate 19-9 antigen (CA 19-9) carnitines (C12, C18, C18:2) N8-acetylspermidine. The reduction CA following correlated negatively deoxycholate levels, latter positively survival. This study revealed neoadjuvant-chemotherapy-induced changes metabolic pathways PDAC, mainly metabolism, these reduced FOLFIRINOX treatment.

Language: Английский

Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer DOI Creative Commons
Manoj Amrutkar,

Sander Johannes Thorbjørnsen Guttorm,

Anette Vefferstad Finstadsveen

et al.

Molecular Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 15, 2024

Neoadjuvant chemotherapy (NAT) is increasingly used for the treatment of non-metastatic pancreatic ductal adenocarcinoma (PDAC) and established as a standard care borderline resectable locally advanced PDAC. However, full exploitation its clinical benefits limited by lack biomarkers that assess response. To address this unmet need, global metabolomic profiling was performed on tumor tissue paired serum samples from patients with treatment-naïve (TN; n = 18) neoadjuvant leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride oxaliplatin (FOLFIRINOX)-treated (NAT; 17) PDAC using liquid chromatography mass spectrometry. Differentially abundant metabolites (DAMs) in TN versus NAT groups were identified their correlation various parameters assessed. Metabolomics 40 five DAMs In general, associated amino acid nucleotide metabolism lower compared to TN. Four DAMs-3-hydroxybutyric (BHB), 3-carboxy-4-methyl-5-propyl-2-furanpropanoic (CMPF), glycochenodeoxycholate citrulline-were common both showed similar pattern differential abundance groups. A strong positive observed between carbohydrate 19-9 antigen (CA 19-9) carnitines (C12, C18, C18:2) N8-acetylspermidine. The reduction CA following correlated negatively deoxycholate levels, latter positively survival. This study revealed neoadjuvant-chemotherapy-induced changes metabolic pathways PDAC, mainly metabolism, these reduced FOLFIRINOX treatment.

Language: Английский

Citations

0